Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free SKYE Stock Alerts

Skye Bioscience (SKYE) Financials

Skye Bioscience logo
$0.63 +0.02 (+3.71%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$0.62 -0.01 (-2.16%)
As of 07/16/2026 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Skye Bioscience

Annual Income Statements for Skye Bioscience

This table shows Skye Bioscience's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -4.84 -3.50 -4.14 -19 1.05 -6.56 -8.52 -19 -38 -31 -56
Consolidated Net Income / (Loss)		 -4.84 -3.18 -3.09 -19 1.05 -6.56 -8.52 -19 -38 -27 -56
Net Income / (Loss) Continuing Operations		 -4.84 -3.18 -3.09 -19 1.05 -6.56 -8.52 -19 -38 -31 -56
Total Pre-Tax Income 		-4.84 -3.18 -3.09 -19 1.05 -6.56 -8.52 -19 -38 -27 -56
Total Operating Income		 -4.32 -4.47 -3.86 -4.69 -6.63 -6.29 -7.85 -18 -35 -30 -58
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 4.32 4.47 3.86 4.69 6.63 6.29 7.85 18 35 34 58
Selling, General & Admin Expense		 3.74 3.53 3.55 4.36 4.39 4.34 4.92 6.09 7.85 18 16
Research & Development Expense		 0.58 0.94 0.31 0.33 2.24 1.94 2.93 6.01 5.82 19 42
Total Other Income / (Expense), net		 -0.52 1.29 0.77 -15 7.69 -0.27 -0.67 -1.16 -2.91 3.64 2.24
Interest Expense		 - 0.00 0.00 0.69 1.73 0.71 0.65 0.67 2.29 0.75 0.00
Interest & Investment Income		 - - 0.00 0.00 0.00 0.00 0.00 0.02 0.10 3.03 1.88
Other Income / (Expense), net		 -0.52 1.29 0.77 -14 9.41 0.44 -0.02 -0.52 -0.72 1.36 0.36
Income Tax Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01
Basic Earnings per Share		 ($0.29) ($0.17) ($0.11) ($0.16) $0.01 ($0.03) ($0.02) ($8.77) ($5.37) ($0.73) ($1.41)
Weighted Average Basic Shares Outstanding		 16.94M 18.95M 27.91M 121.15M 135.15M 230.75M 406.60M 2.22M 7.01M 36.49M 39.66M
Diluted Earnings per Share		 ($0.29) ($0.17) ($0.11) ($0.16) ($0.05) ($0.03) ($0.02) ($8.77) ($5.37) ($0.73) ($1.41)
Weighted Average Diluted Shares Outstanding		 16.94M 18.95M 27.91M 121.15M 169.56M 231.42M 406.60M 2.22M 7.01M 36.49M 39.66M
Weighted Average Basic & Diluted Shares Outstanding		 16.94M 18.95M 27.91M 121.15M 183.21M 350.01M 495.93M 971.55M 56.13M 30.97M 33.38M

Quarterly Income Statements for Skye Bioscience

This table shows Skye Bioscience's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -25 -4.42 -5.02 -7.90 -3.90 -14 -11 -18 -13 -14 -13
Consolidated Net Income / (Loss)		 -25 -4.42 -5.02 -7.90 -3.90 -9.75 -11 -18 -13 -14 -13
Net Income / (Loss) Continuing Operations		 -25 -4.42 -5.02 -7.90 -3.90 -14 -11 -18 -13 -14 -13
Total Pre-Tax Income 		-25 -4.42 -5.02 -7.89 -3.90 -9.75 -11 -18 -13 -14 -13
Total Operating Income		 -25 -4.09 -6.15 -8.41 -4.97 -11 -12 -18 -13 -15 -13
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 25 4.09 6.15 8.41 4.97 15 12 18 13 15 13
Selling, General & Admin Expense		 2.24 2.49 4.21 4.33 4.64 4.55 4.56 3.91 3.91 3.43 4.74
Research & Development Expense		 1.25 1.59 1.95 4.08 4.88 7.79 7.20 14 9.36 11 7.94
Total Other Income / (Expense), net		 -0.24 -0.33 1.13 0.51 1.07 0.92 0.66 0.62 0.51 0.45 0.17
Interest Expense		 0.27 0.43 0.44 0.45 -0.09 -0.05 0.00 0.00 0.00 -0.00 0.00
Interest & Investment Income		 0.02 0.05 0.43 0.96 0.91 0.73 0.62 0.53 0.42 0.31 0.17
Other Income / (Expense), net		 0.01 0.05 1.14 -0.00 0.07 0.14 0.04 0.09 0.09 0.14 -0.00
Income Tax Expense		 0.00 - 0.00 0.01 0.00 - 0.00 0.00 0.00 - 0.00
Basic Earnings per Share		 ($3.17) ($0.03) ($0.18) ($0.20) ($0.10) ($0.25) ($0.28) ($0.44) ($0.32) ($0.37) ($0.32)
Weighted Average Basic Shares Outstanding		 7.88M 7.01M 28.00M 38.67M 38.82M 36.49M 39.65M 39.66M 39.67M 39.66M 39.68M
Diluted Earnings per Share		 ($3.17) ($0.03) ($0.18) ($0.20) ($0.10) ($0.25) ($0.28) ($0.44) ($0.32) ($0.37) ($0.32)
Weighted Average Diluted Shares Outstanding		 7.88M 7.01M 28.00M 38.67M 38.82M 36.49M 39.65M 39.66M 39.67M 39.66M 39.68M
Weighted Average Basic & Diluted Shares Outstanding		 12.34M 56.13M 28.07M 30.34M 30.34M 30.97M 30.98M 30.99M 32.06M 33.38M 35.14M

Annual Cash Flow Statements for Skye Bioscience

This table details how cash moves in and out of Skye Bioscience's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 3.01 -3.16 0.16 1.59 -0.02 0.64 6.51 -7.74 9.09 58 -63
Net Cash From Operating Activities		 -3.73 -3.55 -3.33 -3.94 -6.03 -6.05 -6.47 -13 -14 -25 -43
Net Cash From Continuing Operating Activities		 -3.73 -3.55 -3.33 -3.94 -6.03 -6.05 -6.47 -13 -14 -22 -43
Net Income / (Loss) Continuing Operations		 -4.84 -3.18 -3.09 -19 1.05 -6.56 -8.52 -19 -38 -27 -56
Consolidated Net Income / (Loss)		 -4.84 -3.18 -3.09 -19 1.05 -6.56 -8.52 -19 -38 -27 -56
Depreciation Expense		 0.01 0.01 0.01 0.00 0.00 0.00 0.03 0.11 0.12 0.30 0.72
Amortization Expense		 0.59 0.05 0.03 0.06 0.63 0.54 0.59 0.49 0.33 0.60 0.00
Non-Cash Adjustments To Reconcile Net Income		 1.36 -0.58 0.05 15 -8.01 -0.13 0.76 6.83 24 6.45 7.23
Changes in Operating Assets and Liabilities, net		 -0.84 0.14 -0.32 0.10 0.30 0.09 0.66 -0.69 -0.39 -2.53 4.91
Net Cash From Investing Activities		 -0.00 -0.01 -0.02 -0.00 0.00 -0.01 -0.09 5.21 6.60 -0.25 -20
Net Cash From Continuing Investing Activities		 -0.00 -0.01 -0.02 -0.00 0.00 -0.01 -0.09 5.21 6.60 -0.25 -20
Purchase of Property, Plant & Equipment		 -0.00 -0.01 -0.02 -0.00 0.00 -0.01 -0.09 -0.03 -0.01 -1.60 -0.01
Purchase of Investments		 - - - - - - - - - 0.00 -20
Divestitures		 - - - - - - 0.00 -0.07 5.53 1.36 0.36
Net Cash From Financing Activities		 6.74 0.41 3.51 5.54 6.00 6.70 13 -0.21 16 84 0.03
Net Cash From Continuing Financing Activities		 6.74 0.41 3.51 5.54 6.00 6.70 13 -0.21 16 84 0.03
Issuance of Common Equity		 0.72 0.00 0.00 3.19 6.00 6.13 13 0.00 4.97 0.00 0.03
Other Financing Activities, net		 - - 0.00 - - 0.00 0.02 0.00 12 84 0.00
Cash Interest Paid		 0.00 0.00 0.00 0.02 0.37 0.12 0.04 0.33 0.20 0.43 0.00
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01

Quarterly Cash Flow Statements for Skye Bioscience

This table details how cash moves in and out of Skye Bioscience's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 14 -3.87 82 -9.22 -6.71 -8.08 -22 -23 -5.40 -13 2.27
Net Cash From Operating Activities		 -4.05 -3.84 -4.71 -7.09 -5.26 -8.17 -9.19 -11 -13 -9.77 -8.56
Net Cash From Continuing Operating Activities		 -4.05 -3.84 -4.71 -7.34 -5.02 -4.69 -9.19 -11 -13 -9.77 -8.56
Net Income / (Loss) Continuing Operations		 -25 -4.42 -5.02 -7.90 -3.90 -9.75 -11 -18 -13 -14 -13
Consolidated Net Income / (Loss)		 -25 -4.42 -5.02 -7.90 -3.90 -9.75 -11 -18 -13 -14 -13
Depreciation Expense		 0.03 0.03 0.03 0.03 0.07 0.18 0.18 0.19 0.18 0.18 0.17
Non-Cash Adjustments To Reconcile Net Income		 21 0.41 1.33 1.81 -2.34 5.65 2.20 1.90 1.78 1.39 1.67
Changes in Operating Assets and Liabilities, net		 -0.67 -0.09 -1.29 -1.52 1.05 -0.78 -0.46 4.79 -2.57 3.11 2.10
Net Cash From Investing Activities		 1.07 -0.01 1.14 -0.03 -1.45 0.09 -13 -12 7.97 -2.80 11
Net Cash From Continuing Investing Activities		 1.07 -0.01 1.14 -0.03 -1.45 0.09 -13 -12 7.97 -2.80 11
Purchase of Property, Plant & Equipment		 -0.00 -0.01 -0.00 -0.03 -1.52 -0.05 -0.01 - - - 0.00
Sale of Property, Plant & Equipment		 - - - - - - 0.00 - - - 0.00
Sale and/or Maturity of Investments		 - - - - - - -13 - - - 11
Net Cash From Financing Activities		 17 -0.02 86 -2.10 - 0.01 0.00 0.02 - 0.01 -0.07
Net Cash From Continuing Financing Activities		 17 -0.02 86 -2.10 - 0.01 0.00 0.02 - 0.01 -0.07
Repayment of Debt		 -0.07 -0.03 - - - - 0.00 - - - -0.07
Cash Interest Paid		 - - - - - - 0.00 - - - 0.00
Cash Income Taxes Paid		 - - - - - - 0.00 - - - 0.00

Annual Balance Sheets for Skye Bioscience

This table presents Skye Bioscience's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 3.51 0.32 0.56 1.96 2.00 2.67 9.86 9.11 12 73 28
Total Current Assets		 3.45 0.28 0.56 1.95 1.99 2.66 9.61 8.94 12 71 27
Cash & Equivalents		 3.22 0.06 0.26 1.85 1.83 2.47 8.98 1.24 1.26 68 5.88
Short-Term Investments		 - - - - - - - - - 0.00 20
Prepaid Expenses		 0.16 0.17 0.29 0.09 0.15 0.19 0.55 0.78 0.19 0.20 0.50
Other Current Assets		 0.04 0.01 0.00 0.00 0.01 0.00 0.06 0.48 1.12 2.21 0.85
Plant, Property, & Equipment, net		 0.01 0.01 0.00 0.00 0.00 0.01 0.09 0.09 0.04 1.43 0.90
Total Noncurrent Assets		 0.04 0.03 0.00 0.00 0.00 0.00 0.16 0.08 0.25 0.50 0.32
Other Noncurrent Operating Assets		 0.04 0.03 - - - 0.00 0.16 0.08 0.25 0.50 0.32
Total Liabilities & Shareholders' Equity		 3.51 0.32 0.56 1.96 2.00 2.67 9.86 9.11 12 73 28
Total Liabilities		 3.04 1.77 1.36 18 1.45 2.22 3.99 12 14 4.61 8.29
Total Current Liabilities		 0.58 0.66 0.81 16 0.97 0.79 3.91 12 14 4.34 8.21
Short-Term Debt		 - 0.00 0.24 - 0.00 0.00 1.97 1.85 4.37 - 0.00
Accounts Payable		 0.13 0.27 0.10 0.02 0.14 0.38 0.90 1.79 0.96 0.57 2.03
Accrued Expenses		 0.37 0.27 0.20 - 0.00 - 0.00 6.21 6.26 1.82 2.07
Current Employee Benefit Liabilities		 - - - - - 0.06 0.34 0.66 0.89 1.11 1.27
Other Current Liabilities		 0.08 0.12 0.27 16 0.83 0.34 0.69 1.60 1.06 0.84 2.83
Total Noncurrent Liabilities		 2.46 1.11 0.55 1.58 0.48 1.43 0.08 0.00 0.17 0.27 0.08
Other Noncurrent Operating Liabilities		 2.45 1.11 0.55 0.22 0.09 0.00 0.08 0.00 0.17 0.27 0.08
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -0.89 -2.91 -3.57 -16 0.55 0.45 5.86 -3.01 -2.13 68 20
Total Preferred & Common Equity		 -0.89 -2.91 -3.57 -16 0.55 0.45 5.86 -3.01 -2.13 68 20
Preferred Stock		 - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -0.89 -2.91 -3.57 -16 0.55 0.45 5.86 -3.01 -2.13 68 20
Common Stock		 6.11 7.18 9.48 18 33 39 53 64 102 199 207
Retained Earnings		 -7.76 -11 -14 -33 -32 -39 -47 -67 -104 -131 -187

Quarterly Balance Sheets for Skye Bioscience

This table presents Skye Bioscience's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 16 95 87 82 65 52 41 19
Total Current Assets		 15 95 87 80 63 51 40 19
Cash & Equivalents		 5.13 83 74 67 46 24 18 8.15
Short-Term Investments		 - - - - 13 25 17 8.96
Prepaid Expenses		 0.21 0.64 1.10 0.66 0.58 1.26 3.71 1.22
Other Current Assets		 0.87 1.51 2.71 2.65 3.23 0.73 0.90 0.23
Plant, Property, & Equipment, net		 0.06 0.04 0.05 1.52 1.30 1.17 1.03 0.76
Total Noncurrent Assets		 0.26 0.23 0.21 0.21 0.46 0.41 0.37 0.09
Other Noncurrent Operating Assets		 0.26 0.23 0.21 0.21 0.46 0.41 0.37 0.09
Total Liabilities & Shareholders' Equity		 16 95 87 82 65 52 41 19
Total Liabilities		 14 16 14 5.73 5.54 8.48 8.49 10
Total Current Liabilities		 14 16 14 5.62 5.32 8.31 8.37 10
Short-Term Debt		 4.17 4.61 4.86 0.00 - - - 0.25
Accounts Payable		 1.64 1.10 1.08 0.78 1.71 3.22 2.83 3.94
Accrued Expenses		 6.21 6.05 6.05 1.79 1.91 1.81 2.05 2.57
Current Employee Benefit Liabilities		 0.65 0.35 0.56 0.90 0.66 0.87 0.92 0.23
Other Current Liabilities		 1.05 3.38 1.39 2.15 1.04 2.42 2.57 3.41
Total Noncurrent Liabilities		 0.19 0.15 0.13 0.11 0.22 0.17 0.12 0.00
Other Noncurrent Operating Liabilities		 0.19 0.15 0.13 0.11 0.22 0.17 0.12 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1.70 79 73 76 59 44 33 9.01
Total Preferred & Common Equity		 1.70 79 73 76 59 44 33 9.01
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1.70 79 73 76 59 44 33 9.01
Common Stock		 102 188 190 197 201 203 205 208
Retained Earnings		 -100 -109 -117 -121 -142 -160 -172 -199

Annual Metrics And Ratios for Skye Bioscience

This table displays calculated financial ratios and metrics derived from Skye Bioscience's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 19,278,163.00 20,798,163.00 30,970,663.00 133,870,080.00 134,095,247.00 250,074,415.00 476,108,455.00 912,195,626.00 12,338,910.00 30,338,290.00 32,057,461.00
DEI Adjusted Shares Outstanding		 19,278,163.00 20,798,163.00 30,970,663.00 133,870,080.00 134,095,247.00 250,074,415.00 476,108,455.00 912,195,626.00 12,338,910.00 30,338,290.00 32,057,461.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.25 -0.17 -0.13 -0.14 0.01 -0.03 -0.02 -0.02 -3.05 -1.02 -1.74
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -55.49% 26.73% 1.80% -504.04% 118.49% -255.61% -36.45% -151.68% -92.04% 20.17% -104.30%
EBIT Growth		 -77.16% 34.36% 2.66% -498.56% 115.02% -310.57% -34.45% -139.28% -88.28% 18.66% -100.45%
NOPAT Growth		 -58.04% -3.55% 13.68% -21.59% -101.61% 33.53% -24.78% -133.34% -89.69% 13.08% -92.64%
Net Income Growth		 -77.06% 34.35% 2.64% -520.31% 105.48% -723.74% -29.90% -128.60% -93.23% 29.43% -110.50%
EPS Growth		 -7.41% 41.38% 35.29% -45.45% 68.75% 40.00% 33.33% -43,750.00% 38.77% 86.41% -93.15%
Operating Cash Flow Growth		 -112.40% 4.70% 6.24% -18.36% -52.88% -0.43% -6.95% -96.82% -9.48% -80.89% -70.63%
Free Cash Flow Firm Growth		 23.68% -387.51% 21.51% 448.74% -282.36% 78.37% -4.71% -4.20% -394.10% -12.61% -23.28%
Invested Capital Growth		 -321.82% 44.28% 46.60% -1,836.10% 94.40% 34.46% -94.84% -668.41% 12.35% 96.59% -2,063.89%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 12.71% -18.46% 14.06% -44.27% 138.21% -375.74% -15.28% -72.76% 14.69% -30.72% -8.00%
EBIT Q/Q Growth		 0.50% -15.63% 13.72% -44.21% 129.60% -539.99% -14.51% -66.74% 14.08% -29.02% -7.90%
NOPAT Q/Q Growth		 11.24% 5.14% -1.97% -7.54% -54.98% 7.70% -17.04% -59.37% 13.01% -27.87% -7.84%
Net Income Q/Q Growth		 17.28% -15.62% 13.73% -41.13% 110.49% -3,076.48% -13.46% -60.97% 12.69% -25.08% -9.17%
EPS Q/Q Growth		 32.56% -30.77% 45.00% -45.45% 50.00% -200.00% 0.00% -448.13% 57.07% -43.14% -9.30%
Operating Cash Flow Q/Q Growth		 14.82% 11.26% -80.02% 22.26% -8.83% -4.90% -2.91% -29.49% 6.86% -20.70% -3.84%
Free Cash Flow Firm Q/Q Growth		 -199.12% 17.30% -82.75% 98.69% -1,952.86% 73.42% 4.25% 34.37% -22.00% -18.27% 1.95%
Invested Capital Q/Q Growth		 16.89% -12.83% 61.45% -43.15% 93.77% 59.88% -13.80% -623.99% 7.34% 61.71% -130.73%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.04% 100.05% 100.05% 100.01% 99.85% 100.02% 100.02% 100.03% 100.01% 100.04% 100.01%
Interest Burden Percent		 100.00% 100.00% 100.02% 103.70% 37.90% 112.07% 108.28% 103.43% 106.18% 92.10% 96.74%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.15% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -55,492.45% 648.65% 274.93% 234.62% -14.01% -1,313.66% -269.90% -1,364.20% 1,464.81% -80.48% -126.85%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 4,280,093.44% 2,519.68% 791.91% 274.33% -14.01% -1,313.66% -269.90% -1,364.20% 1,464.81% -80.48% -126.85%
Return on Equity Simple (ROE_SIMPLE)		 542.61% 109.05% 86.69% 123.34% 191.92% -1,455.39% -145.33% 647.65% 1,765.85% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.02 -3.13 -2.70 -3.28 -6.62 -4.40 -5.49 -13 -24 -21 -41
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -104.97% -2.90% -596.55% -6,045.68% 789.39% -173.53% -75.22% -103.87% -233.43% -14.68% -32.31%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -1,085.39% -31.01% -203.33%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.84 -3.18 -3.09 -19 2.78 -5.85 -7.87 -19 -35 -29 -58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.24 -3.11 -3.05 -18 3.41 -5.31 -7.24 -18 -35 -28 -57
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 31.93 22.19 4.22 0.00 0.00 1.26 1.20
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 31.93 22.19 4.22 0.00 0.00 1.26 1.20
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 16.64 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 6.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 4.71 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 5.78 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 4.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 -0.29 -0.09 0.71 3.18 0.34 -0.61 -2.05 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 -0.09 0.71 3.18 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -198.65 3.43 0.06 0.03 0.13 -2.49 -1.28 -4.49 2.22 -1.12 -1.07
Leverage Ratio		 221.19 -3.91 -0.39 -0.15 -0.26 4.67 1.98 6.64 -4.10 1.28 1.15
Compound Leverage Factor		 221.19 -3.91 -0.39 -0.16 -0.10 5.24 2.15 6.87 -4.35 1.18 1.11
Debt to Total Capital		 0.00% 0.00% -41.59% -9.58% 41.39% 76.08% 25.19% -159.39% 195.16% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% -41.59% 0.00% 0.00% 0.00% 25.19% -159.39% 195.16% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% -9.58% 41.39% 76.08% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 289.43% -100.86% -490.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -189.43% 200.86% 631.68% 109.58% 58.61% 23.92% 74.81% 259.39% -95.16% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 -0.08 -0.07 0.11 -0.27 -0.27 -0.10 -0.12 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.01 0.03 -0.42 0.20 0.97 -0.03 0.17 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.07 0.11 -0.27 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.09 -0.41 -0.06 -0.33 -0.36 -0.14 -0.18 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.01 0.15 0.22 0.24 1.28 -0.05 0.25 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.41 -0.06 -0.33 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -4.00 -79.06 -52.02 -61.71 -10.10 -23.98 -4.93 -16.76 -20.83 8.44 -13.44
Noncontrolling Interest Sharing Ratio		 7,812.93% -288.45% -188.04% -16.93% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.94 0.42 0.69 0.12 2.05 3.38 2.46 0.74 0.84 16.32 3.30
Quick Ratio		 5.54 0.10 0.32 0.12 1.89 3.14 2.30 0.10 0.09 15.77 3.14
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.90 -4.36 -3.43 12 -22 -4.71 -4.93 -5.14 -25 -29 -35
Operating Cash Flow to CapEx		 -188,092.28% -31,959.53% -16,949.65% -89,920.50% 0.00% -83,736.25% -7,125.75% -45,417.22% -111,172.73% -1,573.38% -682,232.72%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -5,135.27 17.43 -12.62 -6.67 -7.58 -7.73 -11.10 -38.18 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 -4,994.43 -5.75 -3.49 -8.57 -9.94 -19.16 -6.09 -33.68 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -5,023.90 -5.76 -3.49 -8.58 -10.08 -19.20 -6.10 -35.82 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.79 -1.55 -0.83 -16 -0.90 -0.59 -1.15 -8.83 -7.74 -0.26 -5.71
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -2.13 1.23 0.72 -15 15 0.31 -0.56 -7.68 1.09 7.47 -5.45
Enterprise Value (EV)		 12 7.64 7.45 53 16 8.96 18 15 28 17 -1.70
Market Capitalization		 13 6.28 4.71 54 17 10 25 15 34 86 24
Book Value per Share		 ($0.05) ($0.14) ($0.12) ($0.12) $0.00 $0.00 $0.01 $0.00 ($0.17) $2.25 $0.62
Tangible Book Value per Share		 ($0.05) ($0.14) ($0.12) ($0.12) $0.00 $0.00 $0.01 $0.00 ($0.17) $2.25 $0.62
Total Capital		 0.47 -1.45 -0.57 -14 0.94 1.88 7.84 -1.16 2.24 68 20
Total Debt		 0.00 0.00 0.24 1.36 0.39 1.43 1.97 1.85 4.37 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 1.36 0.39 1.43 0.00 0.00 0.00 0.00 0.00
Net Debt		 -3.26 -0.10 -0.03 -0.50 -1.45 -1.04 -7.01 0.60 -5.96 -68 -26
Capital Expenditures (CapEx)		 0.00 0.01 0.02 0.00 0.00 0.01 0.09 0.03 0.01 1.60 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.39 -0.48 -0.28 -16 -0.81 -0.60 -1.31 -2.58 -8.21 -1.93 -6.85
Debt-free Net Working Capital (DFNWC)		 2.87 -0.38 -0.02 -14 1.02 1.88 7.67 -1.33 2.12 66 19
Net Working Capital (NWC)		 2.87 -0.38 -0.25 -14 1.02 1.88 5.70 -3.18 -2.25 66 19
Net Nonoperating Expense (NNE)		 1.82 0.05 0.39 16 -7.67 2.16 3.03 6.66 13 5.43 15
Net Nonoperating Obligations (NNO)		 -3.26 -0.10 -0.03 -0.50 -1.45 -1.04 -7.01 -5.82 -5.60 -68 -26
Total Depreciation and Amortization (D&A)		 0.60 0.07 0.04 0.06 0.63 0.55 0.63 0.60 0.45 0.90 0.72
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.29) ($0.17) ($0.11) ($0.16) $0.01 ($0.03) ($0.02) ($0.04) ($5.37) ($0.73) ($1.41)
Adjusted Weighted Average Basic Shares Outstanding		 19.90M 25.73M 27.91M 133.91M 135.15M 230.75M 406.60M 555.27M 7.01M 36.49M 39.66M
Adjusted Diluted Earnings per Share		 ($0.29) ($0.17) ($0.11) ($0.16) ($0.05) ($0.03) ($0.02) ($0.04) ($5.37) ($0.73) ($1.41)
Adjusted Weighted Average Diluted Shares Outstanding		 19.90M 25.73M 27.91M 133.91M 169.56M 231.42M 406.60M 555.27M 7.01M 36.49M 39.66M
Adjusted Basic & Diluted Earnings per Share		 ($0.29) ($0.17) ($0.11) ($0.16) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 16.94M 18.95M 100.08M 121.15M 183.21M 350.01M 495.93M 971.55M 56.13M 30.97M 33.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.02 -3.13 -2.70 -3.28 -6.62 -4.40 -5.49 -8.47 -24 -23 -41
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -4,635.73 -27.01 1.61 -8.29 -12.08 -28.31 -15.48 -38.48 0.00
NOPAT to Interest Expense		 0.00 0.00 -4,050.17 -4.79 -3.84 -6.23 -8.44 -19.27 -10.62 -28.21 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 -4,665.19 -27.02 1.61 -8.30 -12.22 -28.35 -15.49 -40.62 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -4,079.63 -4.80 -3.84 -6.24 -8.58 -19.31 -10.63 -30.35 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Skye Bioscience

This table displays calculated financial ratios and metrics derived from Skye Bioscience's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 971,549,608.00 12,338,910.00 28,062,907.00 28,067,907.00 30,338,290.00 30,338,290.00 30,974,558.00 30,984,358.00 30,988,420.00 32,057,461.00 33,378,764.00
DEI Adjusted Shares Outstanding		 971,549,608.00 12,338,910.00 28,062,907.00 28,067,907.00 30,338,290.00 30,338,290.00 30,974,558.00 30,984,358.00 30,988,420.00 32,057,461.00 33,378,764.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.03 -0.36 -0.18 -0.28 -0.13 -0.46 -0.36 -0.57 -0.41 -0.45 -0.37
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -802.37% 61.42% -26.25% -180.57% 80.78% -173.51% -143.32% -121.12% -175.34% -40.83% -8.34%
EBIT Growth		 -746.73% 58.98% -32.13% -186.89% 80.17% -160.53% -134.00% -115.97% -169.02% -40.20% -8.17%
NOPAT Growth		 -745.43% 55.98% -98.45% -195.66% 79.89% -161.02% -91.14% -117.05% -166.96% -39.65% -7.78%
Net Income Growth		 -697.68% 55.32% 2.86% -153.99% 84.37% -120.51% -121.20% -123.02% -227.19% -48.18% -12.66%
EPS Growth		 -100.63% 99.58% 86.86% 75.00% 96.85% -733.33% -55.56% -120.00% -220.00% -48.00% -14.29%
Operating Cash Flow Growth		 -97.16% 21.08% -15.94% -256.13% -29.79% -112.58% -95.10% -51.49% -153.94% -19.50% 6.83%
Free Cash Flow Firm Growth		 -453.65% -435.15% -167.28% -265.23% -9.57% -278.19% -466.18% -44.67% 32.67% 66.68% 94.08%
Invested Capital Growth		 -584.90% 12.35% -18.17% 37.66% 91.74% 96.59% 100.31% 4.64% -259.15% -2,063.89% -29,861.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -748.02% 84.59% -25.35% -71.31% 41.92% -119.32% -11.51% -55.68% 27.68% -12.18% 14.22%
EBIT Q/Q Growth		 -742.68% 83.64% -23.96% -67.85% 41.75% -114.95% -11.34% -54.92% 27.44% -12.02% 14.09%
NOPAT Q/Q Growth		 -769.00% 83.46% -50.56% -36.63% 40.89% -114.66% -10.25% -55.14% 27.29% -12.30% 14.91%
Net Income Q/Q Growth		 -701.73% 82.28% -13.57% -57.44% 50.67% -150.02% -13.92% -58.74% 27.63% -13.23% 13.38%
EPS Q/Q Growth		 -296.25% 99.05% -500.00% -11.11% 50.00% -150.00% -12.00% -57.14% 27.27% -15.63% 13.51%
Operating Cash Flow Q/Q Growth		 -103.57% 5.18% -22.46% -50.67% 25.81% -55.30% -12.39% -16.99% -24.36% 26.92% 12.37%
Free Cash Flow Firm Q/Q Growth		 -286.76% 61.14% 24.53% -201.66% -23.85% -34.12% -12.99% 22.92% 42.36% 33.62% 79.93%
Invested Capital Q/Q Growth		 -1.11% 7.34% -11.44% 40.29% 86.61% 61.71% 109.99% -18,717.77% 49.56% -130.73% -37.34%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.04% 100.10% 100.00% 100.00% 100.02% 100.02% 100.00% 100.00% 100.00%
Interest Burden Percent		 101.03% 109.40% 100.19% 93.92% 79.61% 92.60% 94.73% 97.06% 96.82% 97.87% 98.68%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 5,424.40% 1,464.81% -101.20% -130.08% -54.82% -80.48% -47.27% -72.75% -94.31% -126.85% -167.97%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -127,847.81% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 5,424.40% 1,464.81% -101.20% -130.08% -54.82% -80.48% -47.27% -72.75% -94.31% -126.85% -167.97%
Return on Equity Simple (ROE_SIMPLE)		 -2,543.36% 0.00% -47.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -17 -2.86 -4.31 -5.88 -3.48 -7.47 -8.23 -13 -9.29 -10 -8.87
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -191.83% -27.31% -1.58% -5.15% -0.97% -6.16% -3.91% -7.67% -6.21% -8.53% -9.56%
Return On Investment Capital (ROIC_SIMPLE)		 - -127.69% -5.16% -7.58% -4.59% -10.96% -13.89% -29.24% -28.28% -52.07% -95.79%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -25 -4.04 -5.01 -8.41 -4.90 -11 -12 -18 -13 -15 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -25 -3.78 -4.74 -8.13 -4.72 -10 -12 -18 -13 -15 -13
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2,343.97 0.00 5.56 3.09 1.56 1.26 0.83 2.97 3.71 1.20 2.28
Price to Tangible Book Value (P/TBV)		 2,343.97 0.00 5.56 3.09 1.56 1.26 0.83 2.97 3.71 1.20 2.28
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 2.46 -2.05 0.06 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.03
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 5.02 2.22 -1.21 -1.21 -1.12 -1.12 -1.06 -1.09 -1.03 -1.07 -1.11
Leverage Ratio		 -11.62 -4.10 1.34 1.38 1.25 1.28 1.16 1.20 1.13 1.15 1.23
Compound Leverage Factor		 -11.74 -4.48 1.34 1.29 1.00 1.19 1.09 1.16 1.10 1.12 1.22
Debt to Total Capital		 71.08% 195.16% 5.52% 6.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.70%
Short-Term Debt to Total Capital		 71.08% 195.16% 5.52% 6.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.70%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 28.92% -95.16% 94.48% 93.74% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 97.30%
Debt to EBITDA		 -0.10 -0.12 -0.13 -0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.24 0.17 2.44 1.90 0.00 0.00 0.00 0.00 0.00 0.00 0.29
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.15 -0.18 -0.17 -0.16 0.00 0.00 0.00 0.00 0.00 0.00 -0.01
Net Debt to NOPAT		 0.36 0.25 3.32 2.58 0.00 0.00 0.00 0.00 0.00 0.00 0.41
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 157.34 -12.15 15.72 8.13 11.23 9.27 2.73 4.70 2.63 -8.42 -14.84
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.11 0.84 5.99 6.07 14.19 16.32 11.85 6.09 4.77 3.30 1.78
Quick Ratio		 0.37 0.09 5.27 5.18 11.99 15.77 11.13 5.85 4.22 3.14 1.64
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -10 -3.95 -2.98 -8.99 -11 -15 -17 -13 -7.50 -4.98 -1.00
Operating Cash Flow to CapEx		 -110,392.08% -54,791.48% -148,007.64% -21,851.14% -346.61% -16,338.36% -145,524.08% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -37.46 -9.18 -6.82 -19.98 0.00 0.00 -11,624.48 0.00 0.00 0.00 -454.39
Operating Cash Flow to Interest Expense		 -14.95 -8.94 -10.78 -15.76 0.00 0.00 -6,326.09 0.00 0.00 0.00 -3,891.73
Operating Cash Flow Less CapEx to Interest Expense		 -14.96 -8.95 -10.78 -15.83 0.00 0.00 -6,330.44 0.00 0.00 0.00 -3,891.34
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -8.35 -7.74 -8.62 -5.15 -0.69 -0.26 0.03 -4.91 -2.48 -5.71 -7.85
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -7.13 1.09 -1.33 3.11 7.66 7.47 8.65 0.24 -1.79 -5.45 -7.87
Enterprise Value (EV)		 3,964 28 351 146 42 17 -9.97 81 86 -1.70 3.66
Market Capitalization		 3,974 34 439 225 119 86 49 130 122 24 21
Book Value per Share		 $0.00 ($0.17) $2.81 $2.59 $2.50 $2.25 $1.91 $1.41 $1.06 $0.62 $0.27
Tangible Book Value per Share		 $0.00 ($0.17) $2.81 $2.59 $2.50 $2.25 $1.91 $1.41 $1.06 $0.62 $0.27
Total Capital		 5.86 2.24 83 78 76 68 59 44 33 20 9.26
Total Debt		 4.17 4.37 4.61 4.86 0.00 0.00 0.00 0.00 0.00 0.00 0.25
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -10 -5.96 -88 -78 -76 -68 -59 -49 -35 -26 -17
Capital Expenditures (CapEx)		 0.00 0.01 0.00 0.03 1.52 0.05 0.01 0.00 0.00 0.00 -0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.48 -8.21 -9.04 -5.66 -2.31 -1.93 -1.52 -6.31 -3.76 -6.85 -8.70
Debt-free Net Working Capital (DFNWC)		 5.73 2.12 83 78 74 66 58 42 32 19 8.41
Net Working Capital (NWC)		 1.57 -2.25 79 73 74 66 58 42 32 19 8.16
Net Nonoperating Expense (NNE)		 7.65 1.56 0.71 2.02 0.42 2.28 2.87 4.85 3.47 4.02 3.64
Net Nonoperating Obligations (NNO)		 -10 -5.60 -88 -78 -76 -68 -59 -49 -35 -26 -17
Total Depreciation and Amortization (D&A)		 0.13 0.26 0.26 0.28 0.18 0.18 0.18 0.19 0.18 0.18 0.17
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.17) ($0.03) ($0.18) ($0.20) ($0.10) ($0.25) ($0.28) ($0.44) ($0.32) ($0.37) ($0.32)
Adjusted Weighted Average Basic Shares Outstanding		 7.88M 7.01M 28.00M 38.67M 38.82M 36.49M 39.65M 39.66M 39.67M 39.66M 39.68M
Adjusted Diluted Earnings per Share		 ($3.17) ($0.03) ($0.18) ($0.20) ($0.10) ($0.25) ($0.28) ($0.44) ($0.32) ($0.37) ($0.32)
Adjusted Weighted Average Diluted Shares Outstanding		 7.88M 7.01M 28.00M 38.67M 38.82M 36.49M 39.65M 39.66M 39.67M 39.66M 39.68M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 12.34M 56.13M 28.07M 30.34M 30.34M 30.97M 30.98M 30.99M 32.06M 33.38M 35.14M
Normalized Net Operating Profit after Tax (NOPAT)		 -17 -2.86 -4.31 -5.88 -3.48 -7.47 -8.23 -13 -9.29 -10 -8.87
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -91.01 -9.39 -11.46 -18.68 0.00 0.00 -8,070.88 0.00 0.00 0.00 -5,764.79
NOPAT to Interest Expense		 -63.74 -6.65 -9.86 -13.07 0.00 0.00 -5,669.21 0.00 0.00 0.00 -4,034.59
EBIT Less CapEx to Interest Expense		 -91.02 -9.41 -11.47 -18.75 0.00 0.00 -8,075.23 0.00 0.00 0.00 -5,764.41
NOPAT Less CapEx to Interest Expense		 -63.76 -6.67 -9.86 -13.15 0.00 0.00 -5,673.56 0.00 0.00 0.00 -4,034.20
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Skye Bioscience Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Skye Bioscience's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Skye Bioscience's net income appears to be on an upward trend, with a most recent value of -$55.92 million in 2025, rising from -$4.84 million in 2015. The previous period was -$26.57 million in 2024. See where experts think Skye Bioscience is headed by visiting Skye Bioscience's forecast page.

Skye Bioscience's total operating income in 2025 was -$58.16 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $58.16 million

Over the last 10 years, Skye Bioscience's total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Skye Bioscience's total liabilities were at $8.29 million at the end of 2025, a 79.7% increase from 2024, and a 172.7% increase since 2015.

In the past 10 years, Skye Bioscience's cash and equivalents has ranged from $64.82 thousand in 2016 to $68.42 million in 2024, and is currently $5.88 million as of their latest financial filing in 2025.

Over the last 10 years, Skye Bioscience's book value per share changed from -0.05 in 2015 to 0.62 in 2025, a change of -1,449.0%.


Related Companies

Financial statements for NASDAQ:SKYE last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel